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A B S T R A C T
The role of lipids in the aetiology and progress of Alzheimer’s disease (AD) is still unclear. High lipid levels could be
one of the risk factors for AD, but no association or even protective effects of high cholesterol levels in the development of
the AD were also found. The aim of the study was to determine serum levels of total cholesterol, high-density-lipoprotein
cholesterol (HDL-C), low-density-lipoprotein cholesterol (LDL-C) and triglycerides (TG) in female patients with AD and
in healthy elderly controls. The 50 patients met the diagnostic criteria of probable AD according to the NINDS-ADRDA
and DSM-IV criteria. Cognitive impairment was evaluated using the Mini Mental State Examination (MMSE). Patients
were subdivided into two groups of 19 patients in the middle (MMSE 10-19) and 31 patients in the late (MMSE 0-9) phase
of AD. Psychotic and non-psychotic features, evaluated by means of Neuropsychiatric Inventory, were presented in 13 and
37 patients with AD, respectively. Control group consisted of 58 subjects without cognitive impairment (MMSE>27) and
with lipid levels within normal range. Serum lipid levels were determined by the enzymatic colour tests and by the enzy-
matic clearance assay. Significantly lower lipid levels were found in patients with AD, than in controls. Patients in the
late phase of AD had significantly lower entire lipid profile than controls and significantly lower cholesterol and LDL-C
levels than patients in the middle stage of AD. There was no difference in lipid levels between patients with and without
psychotic features. The significant positive correlations were found between MMSE scores and cholesterol, LDL-C levels
and age in all AD patients. The results support the presumption that lipid profile might be connected with the aetiology
and progress of AD and showed the association between low serum cholesterol and LDL-C levels and cognitive decline in
patients with AD. Further studies are needed to confirm the relationship between lipid levels and cognition, and to vali-
date the lipid profile as a biological marker for the progress of AD.
Key words: Alzheimer’s disease, healthy controls, serum, total cholesterol, high-density-lipoprotein cholesterol, low-
-density-lipoprotein cholesterol, triglycerides, cognitive impairment, psychotic features
Introduction
Alzheimer’s disease (AD) is a complex and progressive
neurodegenerative disorder. Since the prevalence and in-
cidence of AD increase with age, and population world-
wide is getting older, AD is a serious global health prob-
lem. In spite of the intensive investigations, the cause
and progression of AD are not well understood. Two bio-
chemical hallmarks of AD are amyloid-beta peptides (Ab)
gathering in senile plaques, and intracellular accumula-
tion of hyperphosphorylated protein tau in neurofibrilla-
ry tangles1. However, these morphological changes could
only be detected by post-mortem neuropathological exa-
mination2.
A variety of potential peripheral biomarkers for AD
have been investigated in cerebrospinal fluid3 and blood4,5
including biomarkers for lipoproteins metabolism6,7. Li-
pids, and within particularly the cholesterol, are the im-
portant components of the myelin sheath and the mem-
branes of neurons and astrocytes, that play a crucial role
in the development and regulation of synaptic function
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and plasticity. Lipids regulate thickness of cell mem-
brane, its permeability/fluidity and function of mem-
brane-associated proteins (transporters, receptors)8.
Several studies9,10 reported the relationship between
cholesterol levels, amyloid precursor protein (APP) me-
tabolism and apolipoprotein E (ApoE) phenotype, sug-
gesting that cholesterol metabolism might influence the
expression of the APP and Aß in patients with AD1,11,12.
Although clinical and epidemiological data suggest the
aberration of cholesterol homeostasis in AD, it is not
clear if cholesterol has a protective or neurotoxic role in
the development of AD13. Some studies have found that
high lipid levels could be the risk factor for the AD14,
whereas others have shown no association15 or protec-
tive16,17 effects of high lipids on the occurrence of AD.
The longitudinal studies18,19 indicated the decreased pre-
valence of AD, that could be associated with the use of
cholesterol-lowering drugs statins, but their effect could
be independent of the presence or absence of untreated
hyperlipidaemia, and may be due to their well-known an-
tioxidant and anti-inflammatory properties19.
The data regarding blood lipid levels and incidence of
AD are contradictory13. High serum total cholesterol lev-
els may be associated with either increased20, or decr-
eased17 risk for the development of the AD. Lower6,16,22 or
unaltered14 total serum cholesterol levels were found in
AD patients compared to healthy elderly subjects. In addi-
tion, lower high-density lipoprotein cholesterol (HDL-C)
levels in AD patients compared to healthy elderly sub-
jects were found in some14,21 but not all16 studies. Litera-
ture data suggest no alteration in serum triglycerides
(TG) levels in AD14,6,17,21.
The aim of the study was to determine serum total cho-
lesterol, HDL-C, LDL-C and TG levels in female patients
with AD subdivided according to the severity of disease
or the presence of psychotic features and to compare
their values with lipid levels in healthy elderly controls.
Subjects and Methods
The study included 50 female patients with AD (age
X±SD, 79.1±9.0 years, range 56–96 years). All patients
met the diagnostic criteria of the probable AD according
to the Diagnostic and Statistical Manual of Mental Disor-
ders, fourth edition (DSM-IV)22 and the criteria of the
National Institute of Neurologic and Communicative Di-
sorders and Stroke and the Alzheimer's Disease and Re-
lated Disorders Association (NINDS-ADRDA)23. The ex-
clusion criteria for all patients were the diagnoses of
severe somatic diseases, major functional psychiatric dis-
orders, smoking, alcoholism and use of cholesterol-lower-
ing drugs. Cognitive impairment was evaluated using Mi-
ni Mental State Examination (MMSE)24 that was trans-
lated and validated to Croatian population (www.parinc.
com). Patients were subdivided according to the MMSE
scores into two groups: 19 patients (74.8±9.9 years old,
range 56–89 years) in the middle stage of AD with MMSE
scores 15.1±3.5 (range 10–17) and 31 patients (81.7±4.5
years old, range 57–96 years) in the late stage of AD with
MMSE scores 1.6±2.4 (range 0–9). Psychotic features
were evaluated by means of the Neuropsychiatric In-
ventory25. Psychotic and non-psychotic features were
presented in 13 (76.0±11.6 years old, range 56–96 years;
MMSE scores 8±7.5, range 0–16) and 37 (80.1±7.8 years
old, range 57–94 years; MMSE scores 6.1±7.1, range
0–17) patients, respectively. Control group consisted of
58 age-matched healthy older female (71.6±6.2 years old,
range 63–90 years) with lipid levels within normal range
and with MMSE scores from 27 to 30 (28.7±1.2), re-
cruited from the local senior centres. They were evalu-
ated with a clinical interview to rule out for Axis I disor-
ders, current and past medical status and MMSE. Exclu-
sion criteria were the use of cholesterol-lowering drugs,
smoking and alcoholism. Participants or their guardians
gave informed consent. The study was performed in ac-
cordance with the ethical standards laid down in the
1964 Declaration of Helsinki and was approved by the lo-
cal Ethics Committee.
Serum cholesterol, HDL-C and TG levels were deter-
mined by the enzymatic colour test for clinical analyzers,
with the linearity within concentrations range of 0.64–18
mmol/L for cholesterol, 0.05–4.65 mmol/L for HDL-C
and 0.11–11.40 mmol/L for TG. Serum LDL-C levels
were determined by the enzymatic clearance assay, with
linearity up to 22.4 mmol/L.
All data are presented as X±SD. The differences be-
tween groups were assessed by one-way analysis of vari-
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Fig 1. Serum cholesterol, high density lipoprotein cholesterol
(HDL-C) low density lipoprotein cholesterol (LDL-C) and trigly-
cerides (TG) values (X±SD) in healthy controls and in patients
with Alzheimer’s disease (AD) in the middle and late stage of
disease. N is the number of subjects. *p<0.02 vs. healthy con-
trols, **p<0.01 vs. patients in middle stage of AD; #p<0.049 vs.
patients in middle stage of AD; ##p<0.02 vs. healthy controls
(Tukey’s test).
ance (ANOVA), followed by Tukey’s test. The correla-
tions between MMSE scores, age and lipid values were
determined by a Pearson’s coefficient of correlation. The
significance level was p<0.05. The statistical package
used was SigmaStat 3.1 (Jandell Scientific Corp., San Ra-
phael, California, USA).
Results
MMSE scores were significantly (F1,106=406.20;
p<0.001, ANOVA) different between patients with AD
(6.8±7.2) and control women (28.7±1.2). A significant
(F1,48=259.658, p<0.001) difference in the severity of de-
mentia was found within the group of patients with AD,
with higher MMSE scores in patients in the middle
(15.1±3.5) than in patients in the late (1.6±2.4) phase of
AD. Patients with AD were significantly (F1,106=25.636;
p<0.001) older than healthy controls. There was a signifi-
cant difference (F1,48=7.686; p=0.008) in age between
patients with AD subdivided according to the different
phases of the disease. Tukey’s test showed that patients
in the late phase of AD were significantly (p< 0.008)
older than patients in the middle phase of disease.
Serum cholesterol (F1,106=5.54, p<0.020), TG (F1,106=
4.945, p<0.028), LDL-C (F1,106=4.7814, p<0.031) and
HDL-C (F1,106=6.861, p<0.010) levels were significantly
lower in all patients with AD than in healthy subjects
(Table 1). Serum cholesterol (F2,105=6.342, p=0.003),
HDL-C (F2,105=3.779, p=0.026), LDL-C (F2,105=5.272,
p=0.007) and TG (F2,105=3.473, p=0.035) levels were sig-
nificantly different between patients in various stages of
AD and healthy controls. Patients in the late stage of dis-
ease had significantly lower cholesterol, HDL-C, LDL-C
and TG levels than healthy controls (Figure 1), and sig-
nificantly lower cholesterol and LDL-C levels than pa-
tients in the middle stage of disease (Figure 1).
When patients were subdivided according to the pres-
ence of psychotic features, serum cholesterol (F2,105=
3.210, p<0.044), LDL-C (F2,105=3.40, p<0.037) and HDL-
-C (F2,105=3.407, p=0.037) levels differed among psy-
chotic and non-psychotic patients and healthy controls.
AD patients with non-psychotic features had signifi-
cantly lower serum cholesterol, HDL-C and LDL-C val-
ues than healthy controls, while serum TG levels were
similar (F2,105=2.725, p=0.070) among groups (Table 1).
There were no significant (p>0.05) differences in serum
lipid levels between AD patients with psychotic and
non-psychotic features.
The significant correlation was found between MMSE
scores and serum cholesterol (r=0.348, p=0.013) and
LDL-C (r=0.302, p<0.033) levels, but not betweenMMSE
scores and serum HDL-C (r=0.165, p=0.251) and TG
(r=0.174, p=0.236) levels in patients with AD. There
was a significant negative correlation (r= –0.345, p=0.
0142) between MMSE scores and age of patients with
AD. No significant correlation was observed between age
and cholesterol (r=0.024, p=0.860; r=–0.210, p=0.143),
age and HDL-C (r=–0.163, p=0.221; r=–0.051, p=0.725),
age and LDL-C (r=0.124, p=0.926; r=–0.223, p=0.120)
and age and TG (r=0.058, p=0.662; r=–0.232, p=0.105)
levels in healthy controls and patients with AD, respec-
tively.
Discussion
The main findings of the present study are that a) se-
rum lipid levels are reduced in female patients with AD
compared to lipid values in elderly female healthy con-
trols, b) serum lipid levels are the lowest in patients in
the late stage of AD and c) serum lipid levels are not re-
lated to the presence of psychotic features. To the best of
our knowledge, this is the first report of the significantly
lower serum cholesterol and LDL-C levels in patients in
the late phase of AD compared to levels in patients in the
middle phase of AD.
The results of reduced serum cholesterol, LDL-C and
HDL-C levels in patients with AD compared to healthy
controls is in agreement with some previously published
data6,16,21, but are in contrast with elevated LDL-C le-
vels14,26,27 and increased26,27 or unaltered cholesterol14
levels found in patients with AD. The finding that TG
levels are similar between controls and AD patients as a
group is in agreement with other studies14,17. However,
the result of a significantly lower TG levels in patients in
the late phase of AD suggests that TG could be involved
in the progress of AD. Although psychotic features, that
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TABLE 1
SERUM LIPID LEVELS (X±SD) IN PATIENTS WITH ALZHEIMER’S DISEASE SUBDIVIDED ACCORDING TO THE PRESENCE
OF PSYCHOTIC FEATURES AND IN HEALTHY CONTROLS
Patients with Alzheimer’s disease
Healthy controls (58)
All (50)
Psychotic features
With (13) Without (37)
Cholesterol (mmol/L) 5.14±1.18* 5.42±1.21 5.04±1.17* 5.70±1.29
HDL-C (mmol/L) 1.50±0.38* 1.50±0.35 1.51±0.45* 1.71±0.46
LDL-C (mmol/L) 3.03±0.99* 3.36±1.09 2.92±0.94* 3.45±0.97
TG (mmol/L) 1.30±0.65* 1.46±0.73 1.25±0.63 1.66±0.99
* p<0.05 vs. corresponding values in healthy controls (Tukey’s test), HDL-C – high-density-lipoprotein cholesterol, LDL-C – low-den-
sity-lipoprotein cholesterol, TG – triglycerides
distress patients and could be associated with the faster
progress of AD28, were presented in one third of patients,
the results showed no association between lipid levels
and psychotic features and no difference in lipid profile
between patients with and without psychotic features.
The reason for the dissimilar results among studies
might be due to the variety of confounding factors like
age, gender, diet, alcohol, exercise, smoking and different
methods for the determination of lipid levels. To avoid
the complex gender-related differences observed in the
clinical presentation29 and cognitive deficits30 in AD, and
gender related difference in cholesterol, lipoproteins and
apolipoproteins levels observed in healthy subjects31, with
higher serum cholesterol31,32 and HDL-C31,32 and lower
LDL-C32 or TG31 levels in women than in men, present
study included only female subjects. In this respect it is
difficult to compare the results of lipid levels among
studies since several articles did not specified the gen-
der14 of patients with AD or reported lipid levels in the
groups of patients and controls that consisted of both
male and female subjects16,21. Additionally, the severity of
AD or the phases of AD were not specified14,16,21 and dif-
ferent methods i.e. enzymatic21 (present study) or high
performance gel filtration chromatography14, were used
for the determination of serum lipid levels.
Age is also one of the factors that could influence cho-
lesterol values. Aging was associated with the decline in
cholesterol synthesis in hippocampus of healthy sub-
jects33 but not in AD34. Although the patients in the late
stage of AD were the oldest, there was no significant cor-
relation between age and lipid levels in the present study,
suggesting no influence of aging on serum lipid levels.
The most important findings of the present study are
significant differences in total lipid levels among patients
with diverse degrees of the cognitive impairment. The
subdivision of patients with AD according to the cogni-
tive decline has shown that the difference in lipid levels
among healthy controls and patients with AD is due to
the low serum lipid profile in AD patients in the late
stage of the disease. It is noteworthy that all components
of lipid profile were significantly lower in patients in the
late stage of AD compared to values in healthy controls,
while a pronounced decrease in cholesterol and LDL-C
was found in the late stage of AD compared to lipid val-
ues in the middle phases of disease. The results have
shown a positive correlation between MMSE scores and
cholesterol and LDL-C levels in patients with AD indicat-
ing that more severe AD symptoms are associated with
reduced cholesterol and LDL-C values. In the present
study the reduced serum HDL-C levels were also found
in patients with late stage of AD. HDL-C is the choles-
terol fraction, and the key extracellular acceptors for
cholesterol and low HDL-C levels could be associated
with poor memory and progressive decline in memory in
the middle aged adults35, while elevated HDL-C could be
related to decreased incidence of dementia independent
of ApoE status26.
It seems that the data on blood lipid levels and inci-
dence of AD depend on the time when lipid levels were
determined, i.e. over the life course, or in relation to the
underlying course of AD13. Although we have determined
serum lipid levels in patients with AD that were in mid-
dle or late stage of disease, the positive correlation be-
tween MMSE scores and serum cholesterol and LDL-C
levels suggests that increased lipid levels could be the
protective factor in the occurrence of AD. This result is in
agreement with the findings that increased plasma cho-
lesterol levels are associated with a reduced risk of de-
mentia in older subjects17, but is in contrast with the
data from the longitudinal studies showing a positive20,36
or non-significant15,37 association between high choles-
terol and HDL-C levels in midlife and the development of
AD in the late life.
Although peripheral cholesterol content does not con-
tribute to the brain cholesterol levels, because plasma
lipoproteins are unable to cross lipophilic blood-brain
barrier11, and there are many differences between cho-
lesterol metabolism in the brain and periphery13, several
data38,39 suggest that decrease in cerebral cholesterol me-
tabolism could be present in AD. The results of the pres-
ent study on the reduced extra-cerebral, i.e. serum lipid
levels, are in agreement with the decrease in cerebro-
spinal fluid cholesterol and HDL-C40 levels, low hippo-
campal membrane cholesterol levels38, decreased activity
of enzyme seladin-138, and reduced concentration of plas-
ma 24S-hydroxycholesterol levels, which is a marker for
the brain cholesterol metabolism41 in patients with AD.
It is possible that dementia itself modifies lipid levels,
due to the changes in diet or metabolism, leading to low
cholesterol, LDL-C and HDL-c levels in patients with
AD. The role of dyslipidemia in the development and
progress of AD remains unclear. A net flux of peripheral
cholesterol in the form of 27-hydroxycholesterol, a side
chain oxidized cholesterol, through blood-brain-barrier
was reported recently in healthy volunteers42, that could
contribute to the cholesterol homeostasis in the brain
through its effect on several cholesterol-sensitive genes.
A synthesis of cholesterol could be also decreased due to
the lower activity of seladin-1, an enzyme involved in
cholesterol synthesis38.
The limitations of the present study were that the re-
sults are restricted to changes of serum lipid levels, and
that dietary habits of patients were not controlled. Na-
mely, serum lipid levels are partially under influence of
diet11. In contrast to the uncontrolled dietary habits of
the patients in middle stage of AD, patients in the late
stage of AD, who had the lowest lipid levels, were hospi-
talized and fed with the balanced hospital diet, and
therefore the influence of the diet might be excluded.
The advantages of the study were in ethnically uniform
Caucasian sample, matched patients with AD, and el-
derly control group in terms of race, age, gender and in
determination of all components of the lipid profile in
both patients and healthy controls.
In conclusion the results of this study showed the al-
terations in serum lipid levels in patients with AD and
the association between serum cholesterol and LDL-C
and severity of the AD. The mild but significant positive
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correlations between MMSE scores and serum choleste-
rol or LDL-C levels point out to the relationship between
lipid levels and cognition in patients with AD. Further
studies are needed to clarify the role of cholesterol and
lipoproteins in the pathogenesis and progress of the AD.
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KONCENTRACIJA SERUMSKIH LIPIDA U BOLESNIKA S ALZHEIMEROVOM BOLESTI
S A @ E T A K
Uloga lipida u etiologiji i razvoju Alzheimerove bolesti (AB) jo{ uvijek je nejasna. Rezultati dosada{njih istra`ivanja
su pokazali da ne postoji povezanost izme|u serumskih lipida i kognitivnih promjena u oboljelih od AB, ali i protektivni
pa ~ak i pozitivni u~inak povi{enih vrijednosti serumskih lipida u razvoju AB. Cilj istra`ivanja bio je odrediti vrijednosti
ukupnog serumskog kolesterola, lipoproteina velike gusto}e (HDL-C), lipoproteina male gusto}e (LDL-C) i triglicerida
(TG) u 50 `ena oboljelih od AB i u 58 zdravih `ena starije `ivotne dobi. Dijagnoza vjerojatne AB postavljena je na
temelju NINDS-ADRDA i DSM-IV kriterija. Te`ina kognitivnog o{te}enja je procijenjena pomo}u Mini Mental State
Examination (MMSE). Bolesnice su podijeljene u skupinu od 19 bolesnica u srednjoj (MMSE 10-19) i u skupinu od 31
bolesnice u kasnoj (MMSE 0-9) fazi AB. U procjeni psihoti~nih simptoma kori{tena je Neuropsychiatric Inventory.
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Psihoti~ki simptomi su bili prisutni u 13 bolesnica, a bez psihoti~kih simptoma bilo je 37 bolesnica. Kontrolna skupina
bila je sastavljena od `ena starije `ivotne dobi bez kognitivnog o{te}enja (MMSE>27) i s normalnim rasponom koncen-
tracije serumskih lipida. Vrijednosti serumskih lipida odre|ene su enzimatskim testovima. U bolesnica s AB opa`ene su
zna~ajno ni`e vrijednosti serumskih lipida od onih u serumu kontrolne skupine. Bolesnice u kasnoj fazi AB imale su
zna~ajno ni`e vrijednosti svih serumskih lipida od kontrolne skupine, te zna~ajno ni`e vrijednosti ukupnog kolesterola i
LDL-C od oboljelih u srednjoj fazi bolesti. Vrijednosti serumskih lipida nisu bile povezane s psihoti~nim simptomima.
Opa`ena je mala, ali zna~ajna pozitivna korelacija izme|u bodova MMSE i vrijednosti kolesterola ili LDL-C, te izme|u
MMSE i `ivotne dobi bolesnica. Rezultati istra`ivanja upu}uju da bi vrijednosti serumskih lipida mogle biti povezane s
etiologijom i razvojem AB. Pokazana je povezanost izme|u niskih vrijednosti serumskog kolesterola i LDL-C i kogni-
tivnog propadanja u oboljelih od AB. Neophodna su daljnja istra`ivanja kako bi se ustanovilo da li bi vrijednosti serum-
skih lipida mogle biti biolo{ki pokazatelj progresije AB.
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